Cargando…
Overview of the marmoset as a model in nonclinical development of pharmaceutical products
Callithrix jacchus (common marmoset) is one of the more primitive non-human primate species and is used widely in fundamental biology, pharmacology and toxicology studies. Marmosets breed well in captivity with good reproductive efficiencies and their sexual maturity is reached within 18 months of a...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126225/ https://www.ncbi.nlm.nih.gov/pubmed/21156195 http://dx.doi.org/10.1016/j.yrtph.2010.12.003 |
_version_ | 1783516102338281472 |
---|---|
author | Orsi, Antonia Rees, Daryl Andreini, Isabella Venturella, Silvana Cinelli, Serena Oberto, Germano |
author_facet | Orsi, Antonia Rees, Daryl Andreini, Isabella Venturella, Silvana Cinelli, Serena Oberto, Germano |
author_sort | Orsi, Antonia |
collection | PubMed |
description | Callithrix jacchus (common marmoset) is one of the more primitive non-human primate species and is used widely in fundamental biology, pharmacology and toxicology studies. Marmosets breed well in captivity with good reproductive efficiencies and their sexual maturity is reached within 18 months of age allowing for rapid expansion of colonies and early availability of sexually mature animals permitting an earlier assessment of product candidates in the adult. Their relatively small size allows a reduction in material requirements leading to a reduction in development time and cost. Fewer animals are also required due to their ability to be used in both pharmacology and toxicology (nonclinical) studies. These factors, alongside a better understanding of their optimal nutrient and welfare requirements over recent years, facilitate the generation of a more cohesive and robust dataset. With the growth of biotechnology-derived pharmaceuticals, non-human primate use has, by necessity, also increased; nevertheless, there is also a growing public call for minimizing their use. Utilizing, the more primitive marmoset species may provide the optimal compromise and once the scientific rationale has been carefully considered and their use justified, there are several advantages to using the marmoset as a model in nonclinical development of pharmaceutical products. |
format | Online Article Text |
id | pubmed-7126225 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71262252020-04-08 Overview of the marmoset as a model in nonclinical development of pharmaceutical products Orsi, Antonia Rees, Daryl Andreini, Isabella Venturella, Silvana Cinelli, Serena Oberto, Germano Regul Toxicol Pharmacol Article Callithrix jacchus (common marmoset) is one of the more primitive non-human primate species and is used widely in fundamental biology, pharmacology and toxicology studies. Marmosets breed well in captivity with good reproductive efficiencies and their sexual maturity is reached within 18 months of age allowing for rapid expansion of colonies and early availability of sexually mature animals permitting an earlier assessment of product candidates in the adult. Their relatively small size allows a reduction in material requirements leading to a reduction in development time and cost. Fewer animals are also required due to their ability to be used in both pharmacology and toxicology (nonclinical) studies. These factors, alongside a better understanding of their optimal nutrient and welfare requirements over recent years, facilitate the generation of a more cohesive and robust dataset. With the growth of biotechnology-derived pharmaceuticals, non-human primate use has, by necessity, also increased; nevertheless, there is also a growing public call for minimizing their use. Utilizing, the more primitive marmoset species may provide the optimal compromise and once the scientific rationale has been carefully considered and their use justified, there are several advantages to using the marmoset as a model in nonclinical development of pharmaceutical products. Elsevier Inc. 2011-02 2010-12-13 /pmc/articles/PMC7126225/ /pubmed/21156195 http://dx.doi.org/10.1016/j.yrtph.2010.12.003 Text en Copyright © 2010 Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Orsi, Antonia Rees, Daryl Andreini, Isabella Venturella, Silvana Cinelli, Serena Oberto, Germano Overview of the marmoset as a model in nonclinical development of pharmaceutical products |
title | Overview of the marmoset as a model in nonclinical development of pharmaceutical products |
title_full | Overview of the marmoset as a model in nonclinical development of pharmaceutical products |
title_fullStr | Overview of the marmoset as a model in nonclinical development of pharmaceutical products |
title_full_unstemmed | Overview of the marmoset as a model in nonclinical development of pharmaceutical products |
title_short | Overview of the marmoset as a model in nonclinical development of pharmaceutical products |
title_sort | overview of the marmoset as a model in nonclinical development of pharmaceutical products |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126225/ https://www.ncbi.nlm.nih.gov/pubmed/21156195 http://dx.doi.org/10.1016/j.yrtph.2010.12.003 |
work_keys_str_mv | AT orsiantonia overviewofthemarmosetasamodelinnonclinicaldevelopmentofpharmaceuticalproducts AT reesdaryl overviewofthemarmosetasamodelinnonclinicaldevelopmentofpharmaceuticalproducts AT andreiniisabella overviewofthemarmosetasamodelinnonclinicaldevelopmentofpharmaceuticalproducts AT venturellasilvana overviewofthemarmosetasamodelinnonclinicaldevelopmentofpharmaceuticalproducts AT cinelliserena overviewofthemarmosetasamodelinnonclinicaldevelopmentofpharmaceuticalproducts AT obertogermano overviewofthemarmosetasamodelinnonclinicaldevelopmentofpharmaceuticalproducts |